Functional Polymorphisms in FAS/FASL System Increase the Risk of Neuroblastoma in Chinese Population

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Aug 17

PMID 23951214

Citations 26

Authors

Wei Han

Yuling Zhou

Rong Zhong

Chen Wu

Ranran Song

Li Zou

Yan Qiao

Kan Zhai

Jiang Chang

Liming Huang

Li Liu

Xuzai Lu

Jiao Lou

Dianke Yu

Wen Tan

Jinzhe Zhang

Huanmin Wang

Xiaoping Miao

Affiliations

Soon will be listed here.

Abstract

The FAS and FASL system plays a substantial role in apoptosis and immune escape of cells. Three polymorphisms located in the promoter regions of FAS (-1377G/A and -670A/G) and FASL (-844T/C) have been shown to alter the transcriptional activity of the genes, respectively. This study was conducted to evaluate the effects of these polymorphisms on the susceptibility of neuroblastoma in the Chinese population. A total of 203 patients with neuroblastoma and 411 controls were recruited in this case-control study. Polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) was applied for genotyping. Unconditional logistic regression was used to estimate cancer risk by calculating odds ratios (ORs) and their 95% confidence intervals (95% CIs). It was observed that significantly increased risks of neuroblastoma associated with FAS -1377G/A and FASL -844T/C polymorphisms, with ORs equal to 1.55 (95% CI, 1.10-2.20) for FAS -1377 A allele and 2.90 (95% CI, 2.04-4.12) for FASL -844CC genotype carriers compared with non-carriers, respectively. However, no association was found between the polymorphisms of FAS -670A/G and risk of neuroblastoma. In addition, the cumulative effect of FAS and FASL polymorphisms on risk of neuroblastoma was observed (P for trend = 2.502×10(-10)), with OR for the carriers of both FAS -1377A allele and FASL -844CC genotypes equaled to 3.95 (95% CI, 2.40-6.51). This work reveals that polymorphisms of FAS -1377G/A and FASL -844T/C but not FAS -670A/G are associated with risk of neuroblastoma in Chinese. These findings support the hypothesis that genetic polymorphism in FAS/FASL death system may influence individual susceptibility to neuroblastoma.

Citing Articles

Neuroblastoma susceptibility and association of N7-methylguanosine modification gene polymorphisms: multi-center case-control study.

Lin H, Liao F, Liu J, Yang Z, Zhang J, Cheng J Pediatr Res. 2024; 97(1):153-159.

PMID: 38871802 DOI: 10.1038/s41390-024-03318-w.

Genetic variants of m7G modification genes influence neuroblastoma susceptibility.

Liu J, Deng C, Lin H, Zhang X, Zhu J, Zhou C Heliyon. 2024; 10(1):e23658.

PMID: 38173492 PMC: 10761801. DOI: 10.1016/j.heliyon.2023.e23658.

ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.

Consonni F, Gambineri E, Favre C Ann Hematol. 2022; 101(3):469-484.

PMID: 35059842 PMC: 8810460. DOI: 10.1007/s00277-022-04761-7.

gene polymorphisms and neuroblastoma susceptibility in Chinese children.

Li Y, Lu T, Wang J, Zhuo Z, Miao L, Yang Z Aging (Albany NY). 2021; 13(23):25426-25439.

PMID: 34897032 PMC: 8714171. DOI: 10.18632/aging.203760.

Gene rs8756 A>C Polymorphism Reduces Neuroblastoma Risk in Chinese Children: A Four-Center Case-Control Study.

Liu J, Hua R, Cheng Y, Zhu J, Zhang J, Cheng J Onco Targets Ther. 2020; 13:465-472.

PMID: 32021290 PMC: 6970238. DOI: 10.2147/OTT.S229975.

References

Shurin G, Gerein V, Lotze M, Barksdale Jr E . Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand. Nat Immun. 2000; 16(5-6):263-74. DOI: 10.1159/000069452. View

Kushner B, Gilbert F, Helson L . Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer. 1986; 57(9):1887-93. DOI: 10.1002/1097-0142(19860501)57:9<1887::aid-cncr2820570931>3.0.co;2-7. View

Chen W, Zhong R, Ming J, Zou L, Zhu B, Lu X . The SLC4A7 variant rs4973768 is associated with breast cancer risk: evidence from a case-control study and a meta-analysis. Breast Cancer Res Treat. 2012; 136(3):847-57. DOI: 10.1007/s10549-012-2309-9. View

Lagmay J, London W, Gross T, Termuhlen A, Sullivan N, Axel A . Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res. 2009; 15(16):5234-9. PMC: 2740837. DOI: 10.1158/1078-0432.CCR-08-2953. View

Molenaar J, Koster J, Zwijnenburg D, van Sluis P, Valentijn L, van der Ploeg I . Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483(7391):589-93. DOI: 10.1038/nature10910. View

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

Muschen M, Warskulat U, Beckmann M . Defining CD95 as a tumor suppressor gene. J Mol Med (Berl). 2000; 78(6):312-25. DOI: 10.1007/s001090000112. View

Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D . Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004; 96(13):1030-6. DOI: 10.1093/jnci/djh187. View

Bennett M, OConnell J, OSullivan G, Brady C, Roche D, Collins J . The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 1998; 160(11):5669-75. View

10.

Gross N, Balmas K, Beretta Brognara C, Tschopp J . Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma. Med Pediatr Oncol. 2001; 36(1):111-4. DOI: 10.1002/1096-911X(20010101)36:1<111::AID-MPO1026>3.0.CO;2-3. View

11.

Peters A, Kohfink B, Martin H, Griesinger F, Wormann B, Gahr M . Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp Hematol. 1999; 27(5):868-74. DOI: 10.1016/s0301-472x(99)00033-8. View

12.

Suda T, Takahashi T, Golstein P, Nagata S . Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993; 75(6):1169-78. DOI: 10.1016/0092-8674(93)90326-l. View

13.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Garcia-Barcelo M, Yeung M, Miao X, Tang C, Cheng G, Chen G . Genome-wide association study identifies a susceptibility locus for biliary atresia on 10q24.2. Hum Mol Genet. 2010; 19(14):2917-25. PMC: 2893814. DOI: 10.1093/hmg/ddq196. View

16.

Zhong R, Zou L, Sheng W, Zhu B, Xiang H, Chen W . Genetic variations in the TGFβ signaling pathway, smoking and risk of colorectal cancer in a Chinese population. Carcinogenesis. 2013; 34(4):936-42. DOI: 10.1093/carcin/bgs395. View

17.

Huang Q, Morris D, Manolios N . Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997; 34(8-9):577-82. DOI: 10.1016/s0161-5890(97)00081-3. View

18.

Maris J, Mosse Y, Bradfield J, Hou C, Monni S, Scott R . Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008; 358(24):2585-93. PMC: 2742373. DOI: 10.1056/NEJMoa0708698. View

19.

Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L . FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005; 202(7):967-74. PMC: 2213165. DOI: 10.1084/jem.20050707. View

20.

Miao X, Zhang X, Zhang L, Guo Y, Hao B, Tan W . Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. Gastroenterology. 2006; 131(2):420-7. DOI: 10.1053/j.gastro.2006.05.050. View